Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Sphera Funds Management LTD.

Sphera Funds Management LTD. lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 228,776 shares of the biopharmaceutical company's stock after buying an additional 33,427 shares during the period. Ultragenyx Pharmaceutical makes up about 1.7% of Sphera Funds Management LTD.'s portfolio, making the stock its 16th largest position. Sphera Funds Management LTD. owned approximately 0.25% of Ultragenyx Pharmaceutical worth $9,625,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its stake in Ultragenyx Pharmaceutical by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after buying an additional 294 shares during the last quarter. Deep Track Capital LP acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $27,493,000. KBC Group NV raised its stake in Ultragenyx Pharmaceutical by 2,275.8% in the 4th quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company's stock worth $2,567,000 after acquiring an additional 58,442 shares during the last quarter. Dark Forest Capital Management LP purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter valued at about $459,000. Finally, First Light Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 1.1% in the fourth quarter. First Light Asset Management LLC now owns 763,607 shares of the biopharmaceutical company's stock worth $32,125,000 after purchasing an additional 8,505 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, insider John Richard Pinion sold 14,439 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $607,881.90. Following the completion of the sale, the insider now owns 107,766 shares in the company, valued at approximately $4,536,948.60. This trade represents a 11.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. The trade was a 5.16% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 125,405 shares of company stock worth $5,285,169. 5.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on RARE shares. Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Canaccord Genuity Group lifted their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. Morgan Stanley boosted their price objective on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Finally, Piper Sandler decreased their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $90.93.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE traded down $1.81 during midday trading on Wednesday, hitting $35.54. 326,559 shares of the company's stock were exchanged, compared to its average volume of 882,096. The firm's fifty day simple moving average is $36.27 and its 200-day simple moving average is $41.50. The company has a market cap of $3.36 billion, a PE ratio of -5.61 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.59 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The company had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company's quarterly revenue was up 28.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.03) EPS. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.